Skip to main navigation Skip to search Skip to main content

Incorporating genetic testing into the care of patients with amyotrophic lateral sclerosis/frontotemporal degeneration spectrum disorders

Chelsea Chambers*, Lauren Lichten, Ashley Crook, Wendy R. Uhlmann, Laynie Dratch

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose of Review Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) spectrum disorders have a strong genetic component. Genetic counselors are a limited resource, and therefore, other providers must be prepared to integrate genetic testing into their practice. Recent Findings Recent ALS/FTD studies have demonstrated that lack of family history does not preclude a genetic etiology. The benefits of a genetic diagnosis have expanded to include the potential to treat; thus, genetic testing is increasingly recommended to be offered to all persons with ALS/FTD. Summary: Offering genetic testing to persons with ALS/FTD spectrum disorders should be part of routine clinical neurologic care. All genetic testing should include discussion about the medical and psychosocial implications of testing for the patient and family members. Neurologists should be prepared to facilitate this process and recognize when referral to a genetic counselor is indicated.

Original languageEnglish
Article numbere200201
Pages (from-to)1-6
Number of pages6
JournalNeurology: Clinical Practice
Volume13
Issue number5
DOIs
Publication statusPublished - 10 Oct 2023

Fingerprint

Dive into the research topics of 'Incorporating genetic testing into the care of patients with amyotrophic lateral sclerosis/frontotemporal degeneration spectrum disorders'. Together they form a unique fingerprint.

Cite this